Methods 412 HIV/HCV co-infected and treatment naïve individuals with CD4 < 200 cells/ml and HCV viral load >1000 IU/ml were enrolled, and HCV RNA was extracted from patient’s serum. RT-PCR and direct sequencing were employed to resolve sequences encoding Core
and NS5B of HCV for genotyping, and to resolve sequences encoding NS3 protease a.a. 1-200 for detecting DAAs resistance. Results Seven sub-genotypes of HCV were identified from 402 HIV/ HCV co-infected individuals, including 1a, 1b, 2a, 3a, 3b, 6a, 6n. The dominant subgenotype was HCV- 6a (53.35%), followed by HCV-1b (17.86%). One or more mutant sites were found in Tamoxifen clinical trial NS3 protease region of HCV from 90.18% individuals respectively. As main resistant
mutations, D168E was identified in 3 cases (0.78%), A156G was identified in 1 case (0.26%), R155I was identified in 1 case (0.20%), selleck and the minor resistant mutation I132V was identified in 37 cases (9.56%), with T54S in 4 cases (1.03%), Q80K in 197 cases (50.1%), and Q80R in 1 case (0.3%). Same resistant mutations present variant frequencies in different genotypes, such as Q80K was found in 99% HCV-6a. Conclusions In a cohort of 412 HIV/HCV co-infected subjects without either anti-HCV or anti HIV treatment in South China, direct sequencing revealed that HCV-6a was brightly dominant genotype with Q80K resistant mutation in NS3 naturally, and several other NS3-DAAs resistant mutations were also present in treatment naïve HIV/ HCV co-infected population. Disclosures: The following people have nothing to disclose: Fengyu Hu, Zhiwei Liang, Yun Lan, Xiaoping Tang, Weiping Cai Study’s purpose: To compare the safety of latent tuberculosis infection (LTBI) treatment with isoniazid or rifampicin in patients with advanced liver fibrosis consequent to chronic hepatitis C (CHC)
before antiviral treatment including a protease inhibitor (PI) in a country with high incidence of tuberculosis. Patients and methods: Hepatitis C therapy including a PI was indicated to 180 patients with advanced liver fibrosis (F3 and F4 according to METAVIR) between September 2012 and June 2014. The patients ioxilan underwent LTBI screening by tuberculin skin test (TST). Patients with an induration greater than 10mm on TST were treated to LTBI. Isoniazid 300 mg/d during six months was prescribed for patients with liver enzymes lower than three times the upper limit of normality (xULN) and rifampicin 400 mg/d during four months was prescribed to patients with aminotransferases levels equal or higher than 3×ULN. Patients were followed monthly with liver tests and monitored to side effects. Therapy was discontinued if an increase higher than three times the ULN on aminotransferases was observed or if severe gastrointestinal intolerance (GI) happened.